期刊
ONCOIMMUNOLOGY
卷 2, 期 11, 页码 -出版社
TAYLOR & FRANCIS INC
DOI: 10.4161/onci.26441
关键词
cancer therapy; GD2 disialoganglioside; immunocytokine; interleukin-15; RLI superagonist
The use of interleukin (IL)-15 or the IL-15 superagonist RLI as immunological adjuvants presents many advantages over that of IL-2, including a reduced toxicity and an improved efficacy. We have generated an immunocytokine that specifically targets RLI to a tumor-associated antigen, namely, disialoganglioside GD2. This agent displayed robust antitumor activity in 2 syngeneic murine models of malignant disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据